



Axis 7even Historical Testing & Validation Report

Commercial evidence, risk metrics, cross-tier analysis and platform-validation evidence.

VERSION 1.2 · 1 SEPTEMBER 2026

EVIDENCE SCOPE

This report consolidates the standardized Axis 7even commercial evidence available for direct analysis: Focused and Core from 2023 onward and Specialist from 2024 onward. Earlier 2021–2022 development-stage portfolio research is identified separately because it predates the current standardized commercial evidence set and did not include USTEC where validated real-tick USTEC history was unavailable.

01 Executive analytical view

COMMON DEPOSIT

€10,000

annual tests reset

LEVERAGE

1:100

reference portfolio tests

HISTORY QUALITY

99–100% real ticks

2026 cross-broker evidence

RISK PROFILE

STANDARD 1.00x

full tested allocation

The evidence set contains annual reset tests, continuous compounding tests, a strict matched research A/B for the USTEC addition, and a separate MT4/MT5 implementation-validation chain. Annual tests answer how each calendar period behaved from the same starting balance. Continuous tests answer how the portfolio behaved without resetting balance and system chronology at year boundaries.

The primary cross-tier comparison is the identical 2024-01-01 to 2026-08-26 continuous window. Core also has a longer 2023–2026 continuous report, but that extended result is standalone Core evidence and is not used to compare against Specialist.

Research period	Evidence role	Comparability
2021–2022	Earlier portfolio robustness research; USTEC excluded where validated real-tick USTEC history was unavailable.	Development-stage evidence; not numerically merged with the standardized commercial series.
2023	First standardized annual evidence year for Focused and Core.	Comparable within Focused / Core; Specialist not yet in the standardized evidence set.
2024–26 Aug 2026	Standardized annual evidence for the current product family.	Primary annual evidence set; 2024–2026 is also the common three-tier continuous window.

02

Test architecture and evidence rules

Dimension	Reference methodology
Broker / data	BlackBull historical data
Initial deposit	EUR 10,000
Leverage	1:100
History model	Every tick based on real ticks
Risk profile	STANDARD 1.00x
Annual tests	Account resets to EUR 10,000 at the start of each period
Continuous tests	No annual reset; percentage-based sizing compounds from the evolving balance
Focused / Core tester host	USDJPY H1 orchestration context
Specialist tester host	USTEC.f M1 orchestration context
Cross-tier comparison rule	Only identical 2024-01-01 to 2026-08-26 continuous windows are compared across Focused, Core and Specialist

03

Annual reset tests

Each period starts from the same EUR 10,000 balance, making year-to-year regime comparison easier.




Figure 1. Annual reset-test returns. 2026 is through 26 August 2026.




Figure 2. Relative equity drawdown for the same annual reset tests.

● Axis 7even Focused

Period	Net profit	Return	Ending balance	Equity DD	PF	Sharpe	Recovery	Trades
2023	€15,690.84	156.91%	€25,690.84	17.29%	1.46	2.91	3.78	191
2024	€28,778.76	287.79%	€38,778.76	19.46%	1.63	3.95	5.58	203
2025	€23,553.45	235.53%	€33,553.45	21.98%	1.57	3.88	4.37	201
2026 to 26 Aug	€36,490.72	364.91%	€46,490.72	17.18%	1.73	5.03	3.93	134

● Axis 7even

Period	Net profit	Return	Ending balance	Equity DD	PF	Sharpe	Recovery	Trades
2023	€12,446.04	124.46%	€22,446.04	21.96%	1.33	2.22	3.54	272
2024	€35,061.59	350.62%	€45,061.59	23.47%	1.51	3.32	5.31	309
2025	€17,025.00	170.25%	€27,025.00	22.56%	1.38	2.78	3.21	287
2026 to 26 Aug	€64,005.91	640.06%	€74,005.91	17.83%	1.72	5.55	4.17	200

● Axis 7even Specialist

Period	Net profit	Return	Ending balance	Equity DD	PF	Sharpe	Recovery	Trades
2024	€44,377.91	443.78%	€54,377.91	24.43%	1.40	3.76	5.84	690
2025	€31,942.82	319.43%	€41,942.82	22.04%	1.35	3.85	3.96	706
2026 to 26 Aug	€94,042.82	940.43%	€104,042.82	18.33%	1.51	6.24	4.23	494

04 Annual risk and execution diagnostics

These diagnostics add context beyond headline return. Margin level is the minimum tester margin-level statistic reported for the run; payoff ratio is average profitable trade divided by the absolute average losing trade.

● Axis 7even Focused

Period	Equity DD	Balance DD	PF	Sharpe	Recovery	Min margin	Avg W/L	Trades
2023	17.29%	14.04%	1.46	2.91	3.78	323.63%	1.74x	191
2024	19.46%	15.73%	1.63	3.95	5.58	244.28%	1.92x	203
2025	21.98%	20.69%	1.57	3.88	4.37	272.58%	1.76x	201
2026 to 26 Aug	17.18%	16.04%	1.73	5.03	3.93	179.49%	1.63x	134

● Axis 7even

Period	Equity DD	Balance DD	PF	Sharpe	Recovery	Min margin	Avg W/L	Trades
2023	21.96%	18.74%	1.33	2.22	3.54	294.83%	1.79x	272
2024	23.47%	17.90%	1.51	3.32	5.31	224.85%	1.92x	309
2025	22.56%	21.31%	1.38	2.78	3.21	303.34%	1.72x	287
2026 to 26 Aug	17.83%	16.98%	1.72	5.55	4.17	181.71%	1.65x	200

● Axis 7even Specialist

Period	Equity DD	Balance DD	PF	Sharpe	Recovery	Min margin	Avg W/L	Trades
2024	24.43%	18.52%	1.40	3.76	5.84	116.69%	1.76x	690
2025	22.04%	19.98%	1.35	3.85	3.96	118.68%	1.95x	706
2026 to 26 Aug	18.33%	18.65%	1.51	6.24	4.23	99.98%	1.71x	494

DIAGNOSTIC READING

The annual series shows positive Profit Factor in every standardized report, but quality and margin pressure vary by year and product. Specialist carries the tightest reported margin levels, consistent with its additional intraday USTEC activity and specialist execution requirements.

05 Annual-regime observations

- All annual periods in the current commercial evidence set are profitable, but the magnitude varies materially by year. The evidence therefore shows regime sensitivity rather than a flat return profile.
- For Focused, return moved from +156.91% in 2023 to +287.79% in 2024, +235.53% in 2025 and +364.91% in 2026 to 26 Aug. Relative equity DD remained between 17.18% and 21.98% across those periods.
- For Axis 7even, 2025 was materially weaker than 2024 (+170.25% versus +350.62%), while 2026 to 26 Aug was materially stronger at +640.06%. Relative equity DD ranged from 17.83% to 23.47%.

- For Axis 7even Specialist, 2024 and 2025 produced +443.78% and +319.43%, while 2026 to 26 Aug reached +940.43%. Relative equity DD ranged from 18.33% to 24.43%.
- Profit Factor remained above 1.0 in every annual report, while Sharpe and Recovery Factor varied with the market regime and product breadth.

06 Cross-broker robustness — 1 Jan to 26 Aug 2026

The same commercial Focused and Core portfolios were tested on four independent MT5 broker environments over the identical 1 January to 26 August 2026 period. All runs used EUR 10,000, 1:100 leverage and STANDARD risk. The reported history quality is 99–100% real ticks. Broker feeds, H1 candle construction, spreads, contract specifications, margin rules and fills are native to each broker, so exact trade sequences and monetary results are not expected to match.

Product	Broker	History	Net profit	Return	Equity DD	PF	Sharpe	Trades
Focused	BlackBull	100% real ticks	€36,490.72	+364.91%	17.18%	1.73	5.03	134
Focused	Pepperstone	99% real ticks	€43,843.32	+438.43%	20.45%	1.92	5.50	132
Focused	IC Markets	99% real ticks	€38,920.76	+389.21%	18.96%	1.82	5.01	137
Focused	FxPro	99% real ticks	€38,045.31	+380.45%	19.16%	1.80	5.41	135
Core	BlackBull	100% real ticks	€64,005.91	+640.06%	17.83%	1.72	5.55	200
Core	Pepperstone	100% real ticks	€55,108.59	+551.09%	23.48%	1.82	5.35	205
Core	IC Markets	99% real ticks	€55,988.63	+559.89%	19.40%	1.78	5.11	204
Core	FxPro	99% real ticks	€58,309.79	+583.10%	19.35%	1.74	5.49	208

ROBUSTNESS READING

Focused remained profitable across all four broker feeds, with net profit ranging from €36,490.72 to €43,843.32, PF 1.73–1.92 and 132–137 trades. Core remained profitable across all four feeds, with net profit ranging from €55,108.59 to €64,005.91, PF 1.72–1.82 and 200–208 trades. The ranking is not identical by product: Pepperstone is highest for Focused, while BlackBull is highest for Core. This supports broker robustness rather than broker-independent result identity.

07 Continuous compounding tests

Section 03 already showed three consecutive profitable annual periods for each product in this window — 2024, 2025 and 2026 to 26 Aug, each restarting from €10,000. The tests below cover the identical window, but nothing resets: each year's gains become the next year's starting capital. This is the evidence for compounding, not for any single trade or year.




Figure 3. Ending balance on the primary same-period 2024-Aug 2026 continuous comparison.

Product	Window	Ending balance	Net profit	Total return (window)	Equity DD	PF	Sharpe	Trades
Axis 7even Focused	2024-01-01 to 2026-08-26	€750,659.21	€740,659.21	7,406.59%	21.55%	1.80	4.45	553
Axis 7even	2024-01-01 to 2026-08-26	€1,116,080.83	€1,106,080.83	11,060.81%	23.47%	1.80	4.05	819
Axis 7even Specialist	2024-01-01 to 2026-08-26	€1,744,254.87	€1,734,254.87	17,342.55%	24.43%	1.67	4.58	1,916

COMPOUNDING EVIDENCE, NOT A FORECAST

"Total return (window)" is the return over the full ≈2.7-year period shown, not an annualized rate. These figures depend on the same three consecutive profitable years documented in section 03 — not a single outsized trade. Because position sizing is percentage-based, trade size compounds together with the balance, which is why continuous results grow faster than the annual-reset figures. Historical compounding is not a guarantee of future compounding.

Product	Recovery	Balance DD	Min margin	Expected payoff	Avg W/L	Deals
Axis 7even Focused	6.04	20.08%	211.57%	€1,339.35	1.94x	1,106
Axis 7even	6.44	20.54%	224.85%	€1,350.53	2.08x	1,638
Axis 7even Specialist	7.48	21.75%	116.69%	€905.14	2.13x	3,832




Figure 4. Same-period continuous return plotted against relative equity drawdown.

EXTENDED CORE HISTORY

Axis 7even also has a supplementary continuous 2023-01-01 to 2026-08-26 report: ending balance €1,811,786.89, net profit €1,801,786.89, total return 18,017.87%, relative equity DD 21.96%, PF 1.86, Sharpe 3.58, 1,091 trades. It is not used in the three-tier comparison because Specialist begins in 2024.

08 Cross-broker continuous compounding — BlackBull vs Pepperstone

For the uninterrupted 2024-01-01 to 2026-08-26 compounding comparison, only broker runs with both sufficient historical depth and high real-tick quality are used. BlackBull and Pepperstone satisfy that requirement for Focused and Core. IC Markets EU is excluded because the required older H1 history is not available on the tested server; FxPro is excluded because its 2024–2026 run reports only 24% real-tick history quality.

Product	Broker	History	Ending balance	Net profit	Return (window)	Equity DD	PF	Sharpe	Trades
Focused	BlackBull	100% real ticks	€750,659.21	€740,659.21	+7,406.59%	21.55%	1.80	4.45	553
Focused	Pepperstone	99% real ticks	€712,761.80	€702,761.80	+7,027.62%	19.80%	1.83	4.56	575
Core	BlackBull	100% real ticks	€1,116,080.83	€1,106,080.83	+11,060.81%	23.47%	1.80	4.05	819
Core	Pepperstone	99% real ticks	€856,472.18	€846,472.18	+8,464.72%	20.46%	1.69	4.01	845

COMPOUNDING COMPARISON

Focused: BlackBull €740,659.21 versus Pepperstone €702,761.80 net profit, a €37,897.41 difference (+5.4% BlackBull over Pepperstone); equity DD was 21.55% versus 19.80%. Core: BlackBull €1,106,080.83 versus Pepperstone €846,472.18, a €259,608.65 difference (+30.7% BlackBull over Pepperstone); equity DD was 23.47% versus 20.46%. Both brokers remain strongly profitable, but compounding magnifies relatively small differences in signal sequence, execution and earlier account growth.

09 Cross-tier quantitative comparison

+49.3%

Core vs Focused
same-period net profit

+56.8%

Specialist vs Core
same-period net profit

+134.2%

Specialist vs Focused
same-period net profit

21.55–24.43%

DD range
same-period continuous

The common-window results show a step-up in historical return as portfolio breadth increases, accompanied by a more moderate increase in relative equity drawdown. Focused and Core both report PF 1.80 in the common continuous window; Specialist reports PF 1.67 but the highest Sharpe of the three at 4.58 and the highest total return.

INTERPRETATION

The continuous figures are compounded historical results, not annualized forecasts. Percentage-based sizing means the absolute lot size grows and shrinks with balance, so continuous results can become very large over multi-year profitable sequences. They should be read together with drawdown, PF, Sharpe, trade count and the annual-reset evidence.

10 Strict matched USTEC A/B research

Variant	USTEC	Net profit	Ending balance	Equity DD	PF	Sharpe	Trades	Margin level
Core matched baseline	OFF	€1,039,191.24	€1,049,191.24	23.64%	1.79	4.19	818	181.56%
Specialist matched	ON	€1,734,254.87	€1,744,254.87	24.43%	1.67	4.58	1,916	116.69%

+66.9%

Net-profit uplift
USTEC ON vs matched
baseline

+0.79 pp

Equity DD change
23.64% → 24.43%

1,098

Additional trades
matched research window

The matched A/B uses the same USTEC.f M1 host and the same 2024–Aug 2026 window to isolate the effect of adding the USTEC intraday engine. This is supporting research evidence rather than the cross-tier publication comparison.

11

MT4 / MT5 implementation validation

The standard MT4 Strategy Tester cannot reproduce the full synchronized multi-market Axis portfolio in one shared test account. For that reason, MT4 performance is not represented by adding standalone symbol tests. The MT4 editions were instead validated through a layered implementation-evidence framework.

Validation layer	Focused	Core	Technical outcome
Source / configuration	PASS	PASS	Corresponding strategy and shared portfolio logic audited after correcting the audit harness.
Controlled decision parity	360/360 exact	468/468 exact	0 missing / 0 extra trade-affecting candidates; JPY cross-filter also matched.
Synchronized portfolio replay	134/134 entries	200/200 entries	Risk money and volume matched entry-by-entry; canonical realized-profit difference €0.00.

CROSS-PLATFORM CONCLUSION

The completed historical validation establishes equivalent strategy and portfolio decisions when the platform implementations receive equivalent inputs. It does not require native MT4 and MT5 broker feeds, historical databases, spreads or fills to be identical.

12 Evidence inventory

Product / scope	Evidence type	Window	Account treatment	Status
Axis 7even Focused	Annual / partial-year	2023	EUR 10,000 reset	Reference
Axis 7even Focused	Annual / partial-year	2024	EUR 10,000 reset	Reference
Axis 7even Focused	Annual / partial-year	2025	EUR 10,000 reset	Reference
Axis 7even Focused	Annual / partial-year	2026 to 26 Aug	EUR 10,000 reset	Reference
Axis 7even Core	Annual / partial-year	2023	EUR 10,000 reset	Reference
Axis 7even	Annual / partial-year	2024	EUR 10,000 reset	Reference
Axis 7even	Annual / partial-year	2025	EUR 10,000 reset	Reference
Axis 7even	Annual / partial-year	2026 to 26 Aug	EUR 10,000 reset	Reference
Axis 7even Specialist	Annual / partial-year	2024	EUR 10,000 reset	Reference
Axis 7even Specialist	Annual / partial-year	2025	EUR 10,000 reset	Reference
Axis 7even Specialist	Annual / partial-year	2026 to 26 Aug	EUR 10,000 reset	Reference
Axis 7even Focused	Continuous	2024-Aug 2026	No annual reset	Reference
Axis 7even	Continuous	2024-Aug 2026	No annual reset	Reference
Axis 7even Specialist	Continuous	2024-Aug 2026	No annual reset	Reference
Axis 7even	Continuous	2023-Aug 2026	No annual reset	Supplementary
Axis 7even Specialist	Matched A/B research	2024-Aug 2026	USTEC ON vs OFF	Supporting
Focused + Core	MT4/MT5 parity	2026 validation window	Controlled + synchronized replay	Historical validation PASS

13 Analytical limitations and interpretation

- Backtests are historical simulations, not guarantees or forecasts.
- Annual reset tests and continuous tests answer different questions and should not be added together.
- The 2026 period is through 26 August 2026 and is not a full calendar year.
- Earlier 2021–2022 development-stage research is not numerically combined with the current standardized commercial series because the product architecture/evidence basis was different and USTEC was not

available on the validated real-tick basis used later.

- The Specialist evidence begins in 2024 and its reports are sourced from the validated research MasterPortfolioV6 / USTEC.f M1 environment; this provenance should remain attached to Specialist documentation.
- Cross-broker results are not expected to be identical. The 2026 four-broker comparison uses 99–100% real-tick reports, while the long-window broker comparison is intentionally restricted to BlackBull and Pepperstone because of IC Markets history availability and FxPro long-window data quality.
- Cross-platform parity establishes implementation equivalence under equivalent inputs, not identical broker feeds or fills.
- The 30% account drawdown threshold is a shutdown trigger, not a guaranteed maximum loss.